Cooperative Agreement W81XWH1220040

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,995 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Xiretsa Inc., a minority-owned small business located in Santa Barbara, CA. The grant will fund the development of a novel class of antimicrobial compounds called Anti-Infective Conjugated Electrolytes (ACEs) that target the bacterial cell membrane to address the growing threat of antimicrobial resistance. The project...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop small molecule inhibitors of the LpxH enzyme as novel antibiotics to treat multidrug-resistant Enterobacterales infections. The $747,763 award to Duke University will fund the design, synthesis, and optimization of potent LpxH inhibitors with desirable drug-like properties. The project aims to establish the...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $299,163 to Phase Genomics Inc. for a proof-of-concept study to develop a novel antimicrobial approach using mRNA-based delivery of bacteriophage-derived endolysin proteins. The project aims to evaluate whether self-replicating mRNA (repRNA) can successfully express an endolysin targeting vancomycin-resistant Enterococcus faecium (VRE), and...

This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $499,441 to Acepre, LLC to develop a novel brain-targeted delivery system for the compound N-acetylcysteine (TN-NAC) as a potential treatment for Alzheimer's disease (AD). The key objectives of this Phase I STTR study are to: 1) evaluate the toxicity and pharmacokinetic properties of TN-NAC in mice, and 2) test the therapeutic efficacy of TN-NAC in a 3xTG-AD mouse model of...

The National Institutes of Health's National Institute of General Medical Sciences awarded Oragenics, Inc. a $769,962 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to support computer-aided design of novel lantibiotics with improved antibiotic properties from August 1, 2021 to July 31, 2022. Specifically, the awardee will investigate the molecular interaction between the lantibiotic mutacin 1140 and its target in silico to rank analogs, synthesize and...

This $298,045 Project Grant award from the National Institutes of Health's National Center for Advancing Translational Sciences (CFDA 93.350) aims to establish and develop a high-throughput screening (HTS) assay to identify novel bacterial DNA gyrase poisoning inhibitors. The key products and services to be delivered under this one-year award include: Developing a unique HTS assay to rapidly discover bacterial DNA gyrase poisoning inhibitors from small molecule libraries. This assay will...

Life Pharms Inc. received a $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 19, 2025, through August 31, 2027. The award supports the development of LP10581, a novel antifungal therapeutic compound derived from the company's proprietary natural product collection. This small-molecular-weight compound (molecular weight 426) is designed to address the...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 aims to develop a platform for detecting genetic antibiotic resistance motifs that can predict current and future susceptibility to therapeutics. The project will establish the feasibility of leveraging mutational signatures in bacterial DNA to identify antibiotic resistance status, including the potential for rapid development of multi-drug resistance. This approach...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) totals $167,768 and aims to evaluate whether beta-lactam antibiotics increase the risk of acute kidney injury (AKI) in patients receiving immune checkpoint inhibitor (ICI) cancer treatments, compared to fluoroquinolone antibiotics. The award will support a target trial emulation study to assess this...

Summary Mahidol University received a $151,200 Project Grant from the National Institutes of Health's John E. Fogarty International Center (CFDA 93.989, International Research and Research Training program) effective September 16, 2025, through August 31, 2030. The award supports research characterizing the cyclic-di-AMP (c-di-AMP) pathway in Clostridioides difficile as a novel drug target to address antimicrobial resistance (AMR). The research delivers scientific investigation into the...